Nigel Crawford is a Principal Investigator at the National Human Genome Research Institute, National Institutes of Health in Bethesda, Maryland, USA. His research focuses upon how hereditary genetic variation impacts metastasis. One aspect of his research concentrates upon how hereditary modifiers regulate metastasis-specific transcriptional programs in breast cancer. This work utilizes ‘next generation’ sequencing technology to investigate how specific germline modifiers drive metastasis-associated patterns of gene expression within the primary tumor. His second area of research concentrates on defining hereditary modifiers of tumor progression and metastasis in prostate cancer. This is being achieved by introducing germline polymorphism through breeding into a variety mouse models of prostate cancer. Subsequently, modifier loci and modifier genes will be identified using quantitative trait locus analysis. The aim of this research is to translate findings from mouse models into human populations in order to identify the subset of men at high risk of aggressive disease development at the time of diagnosis.
Nigel completed his medical training in the University of Liverpool, UK in 1998. This was followed by a Ph.D. from the University of Louisville in 2004 where he specialized in the molecular genetics of susceptibility to inflammatory bowel disease. He performed his postdoctoral studies in the laboratory of Dr. Kent Hunter, NCI where he focused upon the definition of germline modifiers of metastasis in breast cancer. He left the NCI in September 2009 to start his own laboratory in the NHGRI.
Abstracts this author is presenting: